Cambridge Confidence in Concepts: translating pathophysiological insights for patient benefit
Lead Research Organisation:
University of Cambridge
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
| Patrick Maxwell (Principal Investigator) |
Publications
Read C
(2020)
Apelin peptides linked to anti-serum albumin domain antibodies retain affinity in vitro and are efficacious receptor agonists in vivo.
in Basic & clinical pharmacology & toxicology
Read C
(2016)
Cardiac action of the first G protein biased small molecule apelin agonist.
in Biochemical pharmacology
Robinson EL
(2020)
Genes encoding ACE2, TMPRSS2 and related proteins mediating SARS-CoV-2 viral entry are upregulated with age in human cardiomyocytes.
in Journal of molecular and cellular cardiology
Sawyer T
(2017)
Evaluation of illumination system uniformity for wide-field biomedical hyperspectral imaging
in Journal of Optics
Serrano JC
(2017)
A New Methodology for Incorporating Chiral Linkers into Stapled Peptides.
in Chembiochem : a European journal of chemical biology
Singh H
(2016)
ATP-dependent substrate transport by the ABC transporter MsbA is proton-coupled
in Nature Communications
Tarkin JM
(2017)
Detection of Atherosclerotic Inflammation by 68Ga-DOTATATE PET Compared to [18F]FDG PET Imaging.
in Journal of the American College of Cardiology
Thomas JC
(2016)
Inhibition of Ral GTPases Using a Stapled Peptide Approach.
in The Journal of biological chemistry
| Description | (SilkFUSION) - Genetically engineered human pluripotent stem cells, functionalized silk-fibroin platforms and bio-inks: a novel solution for large-scale ex-vivo platelet production, transfusion and drug research |
| Amount | € 2,998,500 (EUR) |
| Funding ID | 767309 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 11/2017 |
| End | 10/2021 |
| Description | BBSRC DTP PhD studentship |
| Amount | £120,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2017 |
| Description | BHF Translational Award |
| Amount | £248,018 (GBP) |
| Funding ID | TG/15/4/31891 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 03/2017 |
| Description | Biomedical Catalyst: DPFS. MICA: A Developmental Trial of Personalised Medicine for Repurposing Zibotentan, a Selective Endothelin A Receptor Blocker, in Microvascular Angina |
| Amount | £3,003,000 (GBP) |
| Funding ID | MR/S018905/1 |
| Organisation | MRC Biomedical Catalyst Developmental Pathway Funding Scheme (DPFS) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Blood and Transplant Grant |
| Amount | £900,000 (GBP) |
| Organisation | NHS England |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2015 |
| End | 10/2020 |
| Description | COMMIT - Continuous Online Metabolite Monitoring. |
| Amount | £1,137,648 (GBP) |
| Funding ID | NIHR200986 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 03/2024 |
| Description | CRUK Multidisciplinary Project award |
| Amount | £483,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | CRUK Pioneer award |
| Amount | £200,000 (GBP) |
| Organisation | Cancer Research UK |
| Department | CRUK Centre for Cancer Therapeutics |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | Cell death by RNA trans-splicing as a gene therapy for hepatocellular carcinoma |
| Amount | £193,312 (GBP) |
| Funding ID | RG90696 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| Description | CiC-Development of a Transcatheter Mitral Repair System for patients with Mitral Regurgitation |
| Amount | £69,978 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 11/2017 |
| Description | Clinical Research Training Fellowship |
| Amount | £116,678 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2016 |
| End | 08/2019 |
| Description | Combined biomechanical modelling and imaging to predict human atherosclerotic plaque rupture and growth |
| Amount | £109,776 (GBP) |
| Funding ID | RG2638 |
| Organisation | Heart Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 12/2016 |
| Description | Deciphering key switches of platelet formation |
| Amount | £20,000 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2017 |
| End | 07/2018 |
| Description | Development of 3D finite element analysis and imaging to predict human atherosclerotic plaque instability |
| Amount | £249,185 (GBP) |
| Funding ID | PG/18/14/33562 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 03/2021 |
| Description | Gates Scholarship PPR project |
| Amount | £130,000 (GBP) |
| Organisation | Serth and Gates Charitable Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Howe & Nisbet R5.6 - Building collaborations to study parasitic diseases of African livestock |
| Amount | £5,166 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Department | Global Challenges Research Fund |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Howe & Nisbet R5.6 - Plastid Preview 2017 |
| Amount | £2,500 (GBP) |
| Organisation | Gatsby Charitable Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Howe & Nisbet R5.6 - Plastid Preview 2017 |
| Amount | £500 (GBP) |
| Organisation | Company of Biologists |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Howe & Nisbet R5.6 - Plastid Preview 2017 |
| Amount | £1,500 (GBP) |
| Organisation | Company of Biologists |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Howe & Nisbet R5.6 - Plastid Preview 2017 |
| Amount | £1,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Department | Networks in Industrial Biotechnology and Bioenergy (NIBB) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Mechanistic study of the effect of ET-1 SNPs in Coronary Microvascular Disease (PRIZE ET Sub-Study) |
| Amount | £208,976 (GBP) |
| Organisation | J P Moulton Charitable Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2020 |
| End | 01/2023 |
| Description | NIHR i4i |
| Amount | £537,000 (GBP) |
| Funding ID | II-C5-0715-20005 |
| Organisation | National Institute for Health Research |
| Department | NIHR i4i Invention for Innovation (i4i) Programme |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 04/2019 |
| Description | NIHR i4i Challenge Award, Development of microdialysis online sensor technology for use in critical care of acute brain trauma patients |
| Amount | £536,627 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 10/2019 |
| Description | NIHR i4i Product Development Award - COMMIT - Continuous Online Metabolite Monitoring |
| Amount | £1,137,648 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 03/2023 |
| Description | PhD studentship |
| Amount | £128,000 (GBP) |
| Organisation | AstraZeneca |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | Pluripotent Stem and Engineered Cell Platform |
| Amount | £3,000,000 (GBP) |
| Organisation | UK Regenerative Medicine Platform |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 04/2023 |
| Description | Production of HLA-null universal platelets from GMP banked human pluripotent stem cell lines |
| Amount | £208,259 (GBP) |
| Funding ID | MR/P007813/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 09/2017 |
| Description | SBC Grant |
| Amount | £154,000 (GBP) |
| Organisation | Higher Education Funding Council for England |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | SilkFusion: Genetically engineered human pluripotent stem cells, functionalized silk-fibroin platforms and bioinks: a novel solution for large-scale ex-vivo platelet production, transfusion and drug research |
| Amount | € 3,200,000 (EUR) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 11/2017 |
| End | 12/2021 |
| Description | Supercharging Platelets to Prevent Blood Loss after Trauma and Regenerate Hearts after Heart Attacks |
| Amount | £59,450 (GBP) |
| Funding ID | M724 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 10/2020 |
| Description | Targeting Theileria: Identification of novel drug targets against East Coast Fever. |
| Amount | £19,852 (GBP) |
| Organisation | Cambridge-Africa Alborada Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Targeting latent human cytomegalovirus (HCMV) infection by novel chemo and immunotherapeutic strategies to prevent virus reactivation in transplant settings |
| Amount | £448,865 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 07/2017 |
| End | 07/2020 |
| Description | The RIVER Trial |
| Amount | £1,000,007 (GBP) |
| Funding ID | MR/L00528X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | To support research on PPR protein in Toxoplasma gondii. |
| Amount | £10,000 (GBP) |
| Organisation | University of Cambridge |
| Department | Returning Carers Scheme |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Transitioning in vitro platelet production to GMP |
| Amount | £100,000 (GBP) |
| Organisation | Defence Science & Technology Laboratory (DSTL) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 01/2021 |
| Description | Understanding human cytomegalovirus latency as a means to target the latent reservoir |
| Amount | £1,864,411 (GBP) |
| Funding ID | MR/S00081X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 10/2024 |
| Description | Understanding human cytomegalovirus latency as a means to target the latent reservoir |
| Amount | £2,500,000 (GBP) |
| Funding ID | (MR/S00081X/1) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Universal cells to overcome HLA barriers in regenerative medicine |
| Amount | £1,000,000 (GBP) |
| Organisation | UK Regenerative Medicine Platform |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 01/2022 |
| Description | a University HEFCE grant |
| Amount | £204,392 (GBP) |
| Funding ID | RG74090 |
| Organisation | NIHR/HEFCE Higher Education Fund for England |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 03/2017 |
| Description | an electron cryo-microscopy resource for macromolecular structure determination in the University of Cambridge |
| Amount | £1,000,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2016 |
| End | 12/2021 |
| Description | titan krios cryoem |
| Amount | £3,000,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 02/2022 |
| Description | visualising transport dynamics of transmembrane pumps |
| Amount | £1,954,530 (GBP) |
| Organisation | European Commission H2020 |
| Sector | Public |
| Country | Belgium |
| Start | 08/2017 |
| End | 08/2022 |
| Description | BHF translational award workshop |
| Organisation | AstraZeneca |
| Department | MedImmune |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Cyclic Peptide agonists • Discovery of Cyclic Peptide agonists with improved pharmacokinetic and pharmacodynamic properties • Sosei Heptares' Opportunities in Receptor Biology for Industrial Translation (Orbit) Project Grant will translate discoveries during the next three years in animal models of PAH • Evaluation and Option agreement with Sosei Heptares. Company will evaluate peptides discovered by Glen and Davenport • Collaboration between Davenport and Glen continuing on improving PK and PD properties of MM07. • New collaboration on different peptides with Sosei Heptares |
| Collaborator Contribution | Ongoing research with Sosei Heptares, tested over 50 peptide analogues and lead compounds identified following in vivo testing. b) Biased peptide apelin agonists with long plasma half-lives by conjugation with human serum binding domains • Agonists conjugated to AlbudAb antibody to increase plasma half-life (GSK Innovation Funding Opportunity) to link apelin to antibodies to extend the plasma half-life for up to twenty days. This technology is applicable to other peptide ligands which frequently fulfil properties of high affinity and selectivity but plasma half-lives are usually a few minutes. • See below • EMI: Relaxin (AZ) Define study will commence in January 2020 to determine the action of relaxin in human forearm studies c) Apelin receptor antagonists for the treatment of brain cancer, glioblastoma • With collaborators we have discovered our (Glen/Davenport) antagonists have efficacy to block the action of endogenous apelin released from endothelial cells to reduce tumour size in the glioblastoma model of human glioblastoma cells in mouse brain. |
| Impact | regular meetings (each fortnight) and presentations with staff from Sosei Regular meetings with staff from AZ BHF translational award workshop Research carried out by my research group in industry labs (Sosei Heptares, AZ, Takeda) • GSK Innovation Funding Opportunity RG77409 • Sosei Heptares RG86507, RG87431 • AZ RG91869 |
| Start Year | 2019 |
| Description | BHF translational award workshop |
| Organisation | Heptares Therapeutics Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Cyclic Peptide agonists • Discovery of Cyclic Peptide agonists with improved pharmacokinetic and pharmacodynamic properties • Sosei Heptares' Opportunities in Receptor Biology for Industrial Translation (Orbit) Project Grant will translate discoveries during the next three years in animal models of PAH • Evaluation and Option agreement with Sosei Heptares. Company will evaluate peptides discovered by Glen and Davenport • Collaboration between Davenport and Glen continuing on improving PK and PD properties of MM07. • New collaboration on different peptides with Sosei Heptares |
| Collaborator Contribution | Ongoing research with Sosei Heptares, tested over 50 peptide analogues and lead compounds identified following in vivo testing. b) Biased peptide apelin agonists with long plasma half-lives by conjugation with human serum binding domains • Agonists conjugated to AlbudAb antibody to increase plasma half-life (GSK Innovation Funding Opportunity) to link apelin to antibodies to extend the plasma half-life for up to twenty days. This technology is applicable to other peptide ligands which frequently fulfil properties of high affinity and selectivity but plasma half-lives are usually a few minutes. • See below • EMI: Relaxin (AZ) Define study will commence in January 2020 to determine the action of relaxin in human forearm studies c) Apelin receptor antagonists for the treatment of brain cancer, glioblastoma • With collaborators we have discovered our (Glen/Davenport) antagonists have efficacy to block the action of endogenous apelin released from endothelial cells to reduce tumour size in the glioblastoma model of human glioblastoma cells in mouse brain. |
| Impact | regular meetings (each fortnight) and presentations with staff from Sosei Regular meetings with staff from AZ BHF translational award workshop Research carried out by my research group in industry labs (Sosei Heptares, AZ, Takeda) • GSK Innovation Funding Opportunity RG77409 • Sosei Heptares RG86507, RG87431 • AZ RG91869 |
| Start Year | 2019 |
| Description | BHF translational award workshop |
| Organisation | Sosei Group |
| Country | Japan |
| Sector | Private |
| PI Contribution | Cyclic Peptide agonists • Discovery of Cyclic Peptide agonists with improved pharmacokinetic and pharmacodynamic properties • Sosei Heptares' Opportunities in Receptor Biology for Industrial Translation (Orbit) Project Grant will translate discoveries during the next three years in animal models of PAH • Evaluation and Option agreement with Sosei Heptares. Company will evaluate peptides discovered by Glen and Davenport • Collaboration between Davenport and Glen continuing on improving PK and PD properties of MM07. • New collaboration on different peptides with Sosei Heptares |
| Collaborator Contribution | Ongoing research with Sosei Heptares, tested over 50 peptide analogues and lead compounds identified following in vivo testing. b) Biased peptide apelin agonists with long plasma half-lives by conjugation with human serum binding domains • Agonists conjugated to AlbudAb antibody to increase plasma half-life (GSK Innovation Funding Opportunity) to link apelin to antibodies to extend the plasma half-life for up to twenty days. This technology is applicable to other peptide ligands which frequently fulfil properties of high affinity and selectivity but plasma half-lives are usually a few minutes. • See below • EMI: Relaxin (AZ) Define study will commence in January 2020 to determine the action of relaxin in human forearm studies c) Apelin receptor antagonists for the treatment of brain cancer, glioblastoma • With collaborators we have discovered our (Glen/Davenport) antagonists have efficacy to block the action of endogenous apelin released from endothelial cells to reduce tumour size in the glioblastoma model of human glioblastoma cells in mouse brain. |
| Impact | regular meetings (each fortnight) and presentations with staff from Sosei Regular meetings with staff from AZ BHF translational award workshop Research carried out by my research group in industry labs (Sosei Heptares, AZ, Takeda) • GSK Innovation Funding Opportunity RG77409 • Sosei Heptares RG86507, RG87431 • AZ RG91869 |
| Start Year | 2019 |
| Description | BHF translational award workshop |
| Organisation | Takeda Cambridge Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Cyclic Peptide agonists • Discovery of Cyclic Peptide agonists with improved pharmacokinetic and pharmacodynamic properties • Sosei Heptares' Opportunities in Receptor Biology for Industrial Translation (Orbit) Project Grant will translate discoveries during the next three years in animal models of PAH • Evaluation and Option agreement with Sosei Heptares. Company will evaluate peptides discovered by Glen and Davenport • Collaboration between Davenport and Glen continuing on improving PK and PD properties of MM07. • New collaboration on different peptides with Sosei Heptares |
| Collaborator Contribution | Ongoing research with Sosei Heptares, tested over 50 peptide analogues and lead compounds identified following in vivo testing. b) Biased peptide apelin agonists with long plasma half-lives by conjugation with human serum binding domains • Agonists conjugated to AlbudAb antibody to increase plasma half-life (GSK Innovation Funding Opportunity) to link apelin to antibodies to extend the plasma half-life for up to twenty days. This technology is applicable to other peptide ligands which frequently fulfil properties of high affinity and selectivity but plasma half-lives are usually a few minutes. • See below • EMI: Relaxin (AZ) Define study will commence in January 2020 to determine the action of relaxin in human forearm studies c) Apelin receptor antagonists for the treatment of brain cancer, glioblastoma • With collaborators we have discovered our (Glen/Davenport) antagonists have efficacy to block the action of endogenous apelin released from endothelial cells to reduce tumour size in the glioblastoma model of human glioblastoma cells in mouse brain. |
| Impact | regular meetings (each fortnight) and presentations with staff from Sosei Regular meetings with staff from AZ BHF translational award workshop Research carried out by my research group in industry labs (Sosei Heptares, AZ, Takeda) • GSK Innovation Funding Opportunity RG77409 • Sosei Heptares RG86507, RG87431 • AZ RG91869 |
| Start Year | 2019 |
| Description | Collaborative support in the form of a USB snapshot camera package |
| Organisation | XIMEA GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Further development of a novel video-rate near-infrared endoscope |
| Collaborator Contribution | Collaborative support of the research |
| Impact | Publications: 1) doi: 10.1117/1.JBO.21.8.084001 ; 2) https://doi.org/10.1088/2040-8986/aa6176 |
| Start Year | 2015 |
| Description | Funding of RIVER |
| Organisation | Merck |
| Department | Merck Sharp and Dohme Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | - The RIVER trial (collaborations with GSK and MSD). Additional funding for HIV latency research to the Lever through MRC fellowships and grants from the Academy of Medical Sciences and Evelyn Trust: £614,567. (added in Jan 2020) - RIVER trial completed and accepted for publication in Lancet - The CHERUB collaboration aimed at HIV cure supported development of a virus reactivation assay by Wills and Lever, which was a crucially important component of the successful application by CHERUB for MRC DCS funding for a clinical trial that provided £1.7m to support 'RIVER', a randomized clinical study. It was crucial in the validation of viral remission in the recently reported second case of HIV 'cure' (Gupta et al 2019; HIV-1 remission following CCR5?32/?32 haematopoietic stem-cell transplantation; Nature 568, 244-248). |
| Collaborator Contribution | Funding of RIVER: RIVER was funded by the Medical Research Council (Grant ref MR/L00528X/1) in collaboration with support from industry partners. Raltegravir and Vorinostat are manufactured by Merck Sharp and Dohme (MSD). MSD agreed to supply the study drugs free of charge for participants participating in the study. The manufacture of ChAdV63.HIVconsv and MVA.HIVconsv vaccines and all pre-clinical and clinical work to date for these vaccines have been provided free of charge to the RIVER study by Lucy Dorrell and Tomáš Hanke of the University of Oxford utilising their existing MRC grants. GSK own the ChAd vector and have reviewed the RIVER protocol and have approved the use of the ChAdV63.HIVconsv. in the RIVER study. RIVER was run by 'CHERUB', a UK collaboration of five universities pooling their expertise to develop an HIV cure. CHERUB is supported by the National Institute for Health Research and brings together HIV researchers at Imperial College London, the University of Oxford, the University of Cambridge, Medical Research Council Clinical Trials Unit at UCL, and King's College London. RIVER was funded by the Medical Research Council, UK and the industry partners, MSD and GSK. The RIVER trial has now completed |
| Impact | Funding of RIVER: RIVER was funded by the Medical Research Council (Grant ref MR/L00528X/1) in collaboration with support from industry partners. Raltegravir and Vorinostat are manufactured by Merck Sharp and Dohme (MSD). MSD agreed to supply the study drugs free of charge for participants participating in the study. The manufacture of ChAdV63.HIVconsv and MVA.HIVconsv vaccines and all pre-clinical and clinical work to date for these vaccines have been provided free of charge to the RIVER study by Lucy Dorrell and Tomáš Hanke of the University of Oxford utilising their existing MRC grants. GSK own the ChAd vector and have reviewed the RIVER protocol and have approved the use of the ChAdV63.HIVconsv. in the RIVER study. RIVER was run by 'CHERUB', a UK collaboration of five universities pooling their expertise to develop an HIV cure. CHERUB is supported by the National Institute for Health Research and brings together HIV researchers at Imperial College London, the University of Oxford, the University of Cambridge, Medical Research Council Clinical Trials Unit at UCL, and King's College London. RIVER was funded by the Medical Research Council, UK and the industry partners, MSD and GSK. The RIVER trial has now completed and been published |
| Start Year | 2015 |
| Title | Compounds for use as apelin receptor antagonists |
| Description | Davenport, A.P., Maguire, J.J. Glen, R.C., (2019) United Kingdom Patent Application 1805675.4 Compounds for use as apelin receptor antagonists(International Patent Application No. PCT/GB2019/050992 |
| IP Reference | 201980033458.8 ; A+I ref: P032639CN; [AI-WS.FID1024505] |
| Protection | Patent granted |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | Patent holders (Davenport, Maguire Glen) in 2020 assigned above patent to University of Cambridge (via Cambridge Enterprise) to enable grant sponsor Cancer Research UK to progress the international patents. The following are now held by Cambridge Enterprise: Chinese Patent Application No. 201980033458.8 ; A+I ref: P032639CN; [AI-WS.FID1024505] United States Patent Application No. 17/044923; A+I ref: P032639US; [AI-WS.FID1024529] European Patent Application No. 19717580.5; A+I ref: P032639EP; [AI-WS.FID1024517] |
| Title | Compounds for use as apelin receptor antagonists |
| Description | The present inventors have discovered a number of linear peptides which are capable of acting as competitive apelin antagonists which may be useful in the treatment of conditions such as cancer.. |
| IP Reference | PCT/GB2019/050992 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | Commercial In Confidence |
| Impact | These include compounds that are more potent antagonists than the known macrocyclic apelin antagonist MM54 and have an improved pharmacology profile. |
| Title | DEVICE FOR INSERTION INTO HUMAN OR ANIMAL BODY AND ASSOCIATED METHODS |
| Description | An implant device for insertion in a human or animal body comprises a frame, wherein at least a portion of the frame is capable of reversibly transitioning between a solid state rigid mode and a liquid state flexible mode, thereby allowing the device to change its shape. |
| IP Reference | WO2016181138 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Commercial In Confidence |
| Impact | Not yet |
| Title | Trans splicing technology |
| Description | Trans splicing technology being patented by Cambridge Enterprise and licensed to our spinout company |
| IP Reference | |
| Protection | Patent granted |
| Year Protection Granted | |
| Licensed | Yes |
| Impact | The creation of a spin out company, Spliceor Therapeutics has been achieved. |
| Title | - The CHERUB collaboration |
| Description | - The CHERUB collaboration aimed at HIV cure supported development of a virus reactivation assay by Wills and Lever, which was a crucially important component of the successful application by CHERUB for MRC DCS funding for a clinical trial that provided £1.7m to support 'RIVER', a randomized clinical study. It was crucial in the validation of viral remission in the recently reported second case of HIV 'cure' (Gupta et al 2019; HIV-1 remission following CCR5?32/?32 haematopoietic stem-cell transplantation; Nature 568, 244-248). Funding of RIVER: RIVER was funded by the Medical Research Council (Grant ref MR/L00528X/1) in collaboration with support from industry partners. Raltegravir and Vorinostat are manufactured by Merck Sharp and Dohme (MSD). MSD agreed to supply the study drugs free of charge for participants participating in the study. The manufacture of ChAdV63.HIVconsv and MVA.HIVconsv vaccines and all pre-clinical and clinical work to date for these vaccines have been provided free of charge to the RIVER study by Lucy Dorrell and Tomáš Hanke of the University of Oxford utilising their existing MRC grants. GSK own the ChAd vector and have reviewed the RIVER protocol and have approved the use of the ChAdV63.HIVconsv. in the RIVER study. RIVER was run by 'CHERUB', a UK collaboration of five universities pooling their expertise to develop an HIV cure. CHERUB is supported by the National Institute for Health Research and brings together HIV researchers at Imperial College London, the University of Oxford, the University of Cambridge, Medical Research Council Clinical Trials Unit at UCL, and King's College London. RIVER was funded by the Medical Research Council, UK and the industry partners, MSD and GSK. |
| Type | Therapeutic Intervention - Vaccines |
| Year Development Stage Completed | 2019 |
| Development Status | Closed |
| Impact | A panel of 3'exon replacement constructs have been cloned into lentiviral gene transfer vectors for subsequent lentiviral vector production and validation of RNA trans-splicing and killing of HIV-infected cells of the immune system. RNA trans-splicing lentiviral vectors have been produced with detectable lentiviral protein in viral supernatants shown by ELISA. RNA transgene expression is being investigated in transduction experiments, and in some constructs RNA trans-gene expression has been confirmed in a preliminary experiment. Vector transfer and successful trans splicing have been demonstrated with a significant specific killing of HIV infected cells Optimisation of vector production has been achieved and more selective killing of HIV infected versus non infected cells has been seen. The work is now being targeted to attempt to kill cells containing reactivated latent HIV |
| Company Name | Spliceor Therapeutics |
| Description | Spliceor Therapeutics develops medical therapies, specialising in cancer treatments. |
| Year Established | 2020 |
| Impact | N/A |
| Description | "Producing Platelets In Vitro: The Challenges of MK Production and Platelet Release or Clinical Use: Numbers and Quality" |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The focus of this meeting is to bring together our understanding of the processes involved in the development of the megakaryocyte and platelet cell lineage and how these cells can contribute to health and disease. |
| Year(s) Of Engagement Activity | 2019 |
| Description | 'From corals to malaria' |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Talk for Stephen Perse Foundation Sixth Form, Cambridge |
| Year(s) Of Engagement Activity | 2019 |
| Description | 'Imaging your Insides: Stroke and Heart Attack Prevention' |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Dr Teng participated in Homerton 250-- Future visions of healthcare, Homerton College, by giving 'Imaging your Insides: Stroke and Heart Attack Prevention' at 10 Feb 2018 to the general audience. Dr Teng introduced vascular imaging and its application in stroke and heart attack prevention to the audiences from the local community. |
| Year(s) Of Engagement Activity | 2018 |
| Description | - CRUK Innovation Summit 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Ania Piskorz presented at the summit highlighting her entrepreneurship activities involving our recently created startup Tailor Bio and our support from the MRC through the CiC award. This activity created awareness of Ania's science in a commercial setting and has expanded our network and opportunities to commercialise the output of this study. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.cancerresearchuk.org/funding-for-researchers/research-events-and-conferences/innovation-... |
| Description | A novel split mode TFBAR device for quantitative measurements of prostate specific antigen in a small sample of whole blood |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Appearance on - BBC Look East - BBC Breakfast |
| Year(s) Of Engagement Activity | 2020 |
| Description | Abstract selected for short-talk at Single Cell Biology Conference (Wellcome Sanger Institute) virtual edition. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Abstract selected for short talk Virtual edition presented by Carys Johnson, PhD Student at the Wellcome Sanger Institute. |
| Year(s) Of Engagement Activity | 2020 |
| Description | American Peptide Symposium |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | The student presented her work at a conference in the form of a poster. She won a prize for her poster presentation and in light of that was invited to write a review article on her field of study. This article was submitted Jan 2020. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Artemis-A - School visits (e.g Landmark International School, Fulbourn; School visit (Soham Village College, Soham) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | We have presented the Artemis-A and talked about the project in four secondary schools in the area (Cambridge, Ely). These engagement activities were integral to the development of the app but also for informing plans to for how it would successfully be applied within secondary schools for the next stage of the project |
| Year(s) Of Engagement Activity | 2019 |
| Description | Artemis-R |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | this is a network of researchers and practitioners who were interested in supporting mental health in schools. These engagement activities were integral to the development of the app but also for informing plans to for how it would successfully be applied within secondary schools for the next stage of the project. |
| Year(s) Of Engagement Activity | 2020 |
| Description | BPS-MPGPCR 2018 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | This was a research focussed meeting attended by GPCR researchers and industry. This meeting was to disseminate scientific finds. It resulted in us initiated a strong collaboration with the Monash group lead by Sexton and Wootten. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Biochemistry' |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Laboratory practical and introductory lecture for 42 high school students visiting Cambridge from state (i.e. government) schools in the South West of England |
| Year(s) Of Engagement Activity | 2019 |
| Description | British Society for Cardiovascular Research, Coronavirus and the cardiovascular system |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | BSCR reported there were 174 international attendees with a recording made available on the BSCR webpage together with a meeting report including the question and answer session. Positive feedback means BSCR will repeat the format next year. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://bscr.org/event/bscr-autumn-2020-ol/ |
| Description | CLIRSPEC Summer School 2019 - Mid-infrared chemical and Biochemical sensors |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Undergraduate students |
| Results and Impact | Farah Alimagham attended a Summer School on Clinical Spectroscopy - CLIRSPEC Summer School 2019 - approx. 50 attendees, international, 2th- 5th July 2019, Low Wood Bay, Windermere, UK - and gave a short (approx. 10 min) talk entitled "Mid-infrared chemical and Biochemical sensors", not directly mentioning our sensor due to IP issues (and the fact that at the time of the Summer School we were still filling for the patent), but she mentioned continuous monitoring using mid-IR and also her porous silicon on fibre-work which we had published. |
| Year(s) Of Engagement Activity | 2019 |
| Description | COVID-19 treatments called into question |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | There was optimism when UK Health Secretary Matt Hancock announced that a drug called remdesivir, which appears to shorten recovery time by about four days for people with Covid 19, is being made available on the NHS. The Health Secretary said it was probably the biggest step forward in the treatment of seriously ill patients since the crisis began. On the other hand it turns out a drug being touted, and taken, by President Trump isn't reliably good after all. The effect of hydroxychloroquine has been called into question after an analysis by American researchers who say it might even make things worse. While their study has limitations - particularly the fact that they looked at the drugs' effects at very high dose - the World Health Organisation has suspended trials of hydroxychloroquine, along with those of another chemically similar drug called chloroquine. The research has been published in the Lancet medical journal, and Phil Sansom has been discussing the drugs with Cambridge University pharmacologist, Anthony Davenport... |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.thenakedscientists.com/articles/interviews/covid-19-treatments-called-question |
| Description | CRUK Single Cell Workshop in Southampton 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Here we presented some preliminary results on using our protocol to explore ongoing chromosomal instability in ovarian cancer cell lines. The presentation was well received and provided validation of our approach for research use. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.eventbrite.co.uk/e/single-cell-analysis-in-cancer-a-workshop-tickets-64716482742?utm_cam... |
| Description | Cambridge-AstraZeneca Symposium |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | AstraZeneca and University of Cambridge are holding a joint virtual Science Symposium, with sessions including disease models, pre-clinical and clinical research,data science and the use of AI in medicine. It aims to showcase the very best science from collaborations between AstraZeneca and the University of Cambridge, foster inspiration and identify further areas for collaboration between the two organisations. Attendees will hear from the scientists first-hand and interact with specialists and leaders in the field. My participation led to new potential collaboration with Astra Zeneca. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.c2d3.cam.ac.uk/events/astrazeneca-and-university-cambridge-virtual-symposium |
| Description | Centre33 quarterly staff meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of the project to a CPD session for Centre 33 practitioners. These engagement activities were integral to the development of the app but also for informing plans to for how it would successfully be applied within secondary schools for the next stage of the project |
| Year(s) Of Engagement Activity | 2019 |
| Description | Clinical Validation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Catch -up school vision screening programme : 10,000 children have missed vision screening due to Covid in Cambridgeshire - collaboration between NWAFT, CUH and CCS Trusts will enable virtual vision screening to detect vision problems and avoid resultant visual impairment. led to clinical use within CUH and Cambridgeshire Community Trust Plans made for future related activity Own/Colleagues reported change in views or opinions Audience reported changes in views, opinions or behavious De |
| Year(s) Of Engagement Activity | 2021 |
| Description | Coeliac UK online gala dinner |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker at Coeliac UK online gala dinner, November 2020 |
| Year(s) Of Engagement Activity | 2020 |
| Description | Coeliac disease: can we diagnose it better? |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Representing advances in coeliac disease research in the UK at the 18th International Coeliac Disease Symposium, Paris, Sept 2019 |
| Year(s) Of Engagement Activity | 2008,2019 |
| Description | Coral reefs, malaria and drug discovery' |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Public lecture, Cambridge Science Festival |
| Year(s) Of Engagement Activity | 2019 |
| Description | Development of a Removable Transcatheter Valve as an Alternative to Surgical Valve Replacement for Aortic Stenosis |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Article in Heart Matters, the BHF magazine: Development of a Removable Transcatheter Valve as an Alternative to Surgical Valve Replacement for Aortic Stenosis |
| Year(s) Of Engagement Activity | 2017 |
| Description | Development of microdialysis online-sensor technology for use in the neurocritical care of patients with acute brain injury |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Our outreach activities on critical care of acute brain trauma patients (the field to which our CiC work relates) include the following presentations: 1) Cambridge Science Festival (20.3.2016); 2) Women in Science Festival for 6th form students (Robinson College, 22.9.2016); 3)Celebrating Success in Access to HE Diploma Science (Royal Society of Chemistry, London, 4.10.2016). |
| Year(s) Of Engagement Activity | 2016 |
| Description | Differentiation of human pluripotent stem cells to megakaryocytes by forward programming |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Innovative cellular approaches for transfusion medicine |
| Year(s) Of Engagement Activity | 2019 |
| Description | Focus group with GPs/clinicians |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation and discussion around the technology and potential usability in the clinical setting |
| Year(s) Of Engagement Activity | 2019 |
| Description | Insights into Plastid evolution from dinoflagellate algae |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | NK |
| Year(s) Of Engagement Activity | 2019 |
| Description | International Union of Basic and Clinical Pharmacology |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | IUPHAR reported nearly 100 international attendees with a meeting report available on the IUPHAR website. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Invited Speaker at MRC Centre for Regenerative Medicine, Edinburgh |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Requests for further information |
| Year(s) Of Engagement Activity | 2020 |
| Description | Invited speaker at Columbia, Genetics and Development Seminar Series, New York |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker at Columbia, Genetics and Development Seminar Series, New York, United States. (Virtual seminar) Requests for further information. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Invited speaker at IBSC virtual seminar, University of Exeter |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker at IBSC virtual seminar, University of Exeter - Requests for further information |
| Year(s) Of Engagement Activity | 2012,2021 |
| Description | Invivoscribe's European dinner, European Haematology Association, Amsterdam |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | N/A |
| Year(s) Of Engagement Activity | 2019 |
| Description | Pathological Society of Great Britain and Ireland |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | n/z |
| Year(s) Of Engagement Activity | 2019 |
| Description | Pharmacology December 2020 BPS |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This is the flagship BPS meeting each year. Over 1100 people registered virtually including researchers of all career stages, clinicians, publishers and teachers. Focus was to disseminate information. Outcoems have been interactions with pharma and other researchers. |
| Year(s) Of Engagement Activity | 2006,2020 |
| Description | Pint of Science is an annual science festival that takes place every May and brings researchers to your local pub to show you the latest happenings in the world of science. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Pint of Science (2016): Delivered a lecture paired with optics demonstrations to illustrate novel endoscopic imaging to the public |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://pintofscience.co.uk/ |
| Description | Pint of Science presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Development of a Removable Transcatheter Valve as an Alternative to Surgical Valve Replacement for Aortic Stenosis |
| Year(s) Of Engagement Activity | 2017 |
| Description | RSC Emerging Technologies Competition 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | The University of Cambridge has developed a new class of therapeutic metalloproteins that allows controlled and targeted delivery of carbon monoxide into tumours. The compounds, developed by Gonçalo Bernardes, led to strong immune-mediated tumour growth retardation in tumour-bearing mice. Gonçalo Bernardes was awarded the 2nd prize in Healthcare |
| Year(s) Of Engagement Activity | 2015 |
| Description | RadNet Steering Committee meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | RadNet Steering Committee meeting. The study was chosen to present as a collaboration piece for the CRUK RadNet network. The most important impact was to get agreement from all 6 CRUK RadNet centres to join the study. |
| Year(s) Of Engagement Activity | 2020 |
| Description | SBC news article |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Industry/Business |
| Results and Impact | The confidential nature of our data limits further engagement at the moment |
| Year(s) Of Engagement Activity | 2019,2020 |
| Description | Sensors Day 2018 "Design and Development of Mid-infrared Optical Sensors". |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Farah Alimagham also attended Sensors Day 2018, 10 October 2019, Fitzwilliam College, Cambridge (conference organised by the Sensor CDT), where she presented a poster entitled: "Design and Development of Mid-infrared Optical Sensors". It was very general and included continuous biofluid monitoring (as a general topic), bioreactor monitoring, and the use of meta materials for high-sensitivity chemical sensing. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Sensors in Medicine 2019, London |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | At Sensors in Medicine 2019 (see above), Farah Alimagham presented a poster featuring our sensor. The title was "Mid-IR Sensor Systems & Devices for Medical Diagnostics and Monitoring" and the authors were Farah Alimagham, Tanya Hutter, Keri Carpenter, Peter Hutchinson, and Stephen R Elliott. This won Best Poster prize. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Soapbox Science (2016): Stood on a soapbox in Cambridge Market Square |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | Stood on a soapbox in Cambridge Market Square explaining the concepts of wavelength and polarization, illustrating how they might be used in diagnosis of cancer. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://soapboxscience.org/soapbox-science-2016-cambridge/ |
| Description | Targeted delivery of CO using artificial metalloproteins: CO's immunomodulatory properties for cancer therapy |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | "Targeted delivery of CO using artificial metalloproteins: CO's immunomodulatory properties for cancer therapy". Presentation about the technology "artificial metalloproteins for targeted delivery of CO in cancer therapy" at the RSC Emerging Technologies Competition 2015 (awarded the 2nd prize in Healthcare) |
| Year(s) Of Engagement Activity | 2015 |
| Description | The 11th International Retroviral Nucleocapsid and Assembly Symposium |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | The IRNCAS meeting is the The 11th International Retroviral Nucleocapsid and Assembly Symposium held in North Eastern University in Boston and was an international science conference with scientists in the audience from all parts of the world |
| Year(s) Of Engagement Activity | 2019 |
| Description | The NIHR Applied Research Centre (ARC) East of England |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | These engagement activities are integral to the development of the app but also for informing plans to for how it would successfully be applied within secondary schools for the next stage of the project |
| Year(s) Of Engagement Activity | 2021 |
| Description | University of Cambridge Primary School - "We are Scientists" |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | University of Cambridge Primary School: Our school outreach talk was part of an online event called "We are Scientists" at the University of Cambridge Primary School, which took place on 9th Nov 2020. Our talk was titled "We are Neuroscientists: studying the brain". It was a pre-recorded slide presentation with narration, followed by a live (via Microsoft Teams) Q&A session in which the audience of school-children asked us questions. The audience was local, approx. 60 staff and pupils. This talk is now on YouTube. |
| Year(s) Of Engagement Activity | 2020 |
| Description | University of Cambridge Virtual Summer Festival of Learning "Neuroscience: unravelling the brain" |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | We achieved success with our pre-recorded talk, titled "Neuroscience: unravelling the brain" narrated by Prof Hutchinson, which was part of the University of Cambridge Virtual Summer Festival of Learning online programme (6th-24th July 2020), which was an international event. Ours was in the Free Open Talks section, free-to-access by members of the public - our talk had 190 views. This talk is now on YouTube. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Workshop for the Institute of Physics, CamAWiSE, and Schlumberger Gould Research Center |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Novel Imaging for Cancer |
| Year(s) Of Engagement Activity | 2015 |
| URL | https://camawise.org.uk/2015/10/16/novel-imaging-for-cancer-dr-sarah-bohndiek-by-raheela-rehman/ |
| Description | the manufacturing of blood cells in vitro |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | generated a movie to answer these questions_this has been distributed through YouTube (1.5k views) and Tweeter (via the Cambridge Stem Cell Institute_>20,000 hits |
| Year(s) Of Engagement Activity | 2020 |